Amgen Presents New Data For IMDELLTRA In Small Cell Lung Cancer At WCLC 2024; DeLLphi-303 Study Results Show Potential For IMDELLTRA In Combination With A PD-L1 Inhibitor As First-Line Maintenance Therapy In ES-SCLC
Amgen Presents New Data For IMDELLTRA In Small Cell Lung Cancer At WCLC 2024; DeLLphi-303 Study Results Show Potential For IMDELLTRA In Combination With A PD-L1 Inhibitor As First-Line Maintenance Therapy In ES-SCLC
IMDELLTRA will be featured in two oral presentations at the "DLL3 Targeting BiTE Therapies in SCLC" session, taking place today at 2:00 p.m. PDT. New data from the global Phase 1b DeLLphi-303 study of IMDELLTRA combined with PD-L1 inhibitors in first-line maintenance extensive-stage small cell lung cancer (ES-SCLC) will be presented as a late-breaking abstract (#LBA OA10.04). Additionally, long-term results from the Phase 2 DeLLphi-301 study in previously treated ES-SCLC will be highlighted as an oral presentation (#OA10.03).DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC
Dellphi-303 研究結果顯示，IMDELLTRA 與 PD-L1 抑制劑聯合用作 ES-SCLC 的一線維持療法的潛力
DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA
Dellphi-301 長期隨訪數據顯示 IMDELLTRA 持續的安全性和有效性
THOUSAND OAKS, Calif., Sept. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data showcasing IMDELLTRATM (tarlatamab-dlle), a first-in-class delta-like ligand 3 (DLL3)-targeting Bispecific T-cell Engager (BiTE) molecule, at the 2024 World Conference on Lung Cancer (WCLC) in San Diego.
加利福尼亞州千橡市，2024年9月9日 /PRNewswire/ — 安進（納斯達克股票代碼：AMGN）今天宣佈在2024年世界肺癌大會（WCLC）上公佈了新數據，該數據顯示了同類首創的靶向雙特異性T細胞Engager（BiTE）分子的同類首創的靶向三角洲樣配體（DLL3）（BiTE）在聖地亞哥。
IMDELLTRA will be featured in two oral presentations at the "DLL3 Targeting BiTE Therapies in SCLC" session, taking place today at 2:00 p.m. PDT. New data from the global Phase 1b DeLLphi-303 study of IMDELLTRA combined with PD-L1 inhibitors in first-line maintenance extensive-stage small cell lung cancer (ES-SCLC) will be presented as a late-breaking abstract (#LBA OA10.04). Additionally, long-term results from the Phase 2 DeLLphi-301 study in previously treated ES-SCLC will be highlighted as an oral presentation (#OA10.03).
IMDELLTRA將在太平洋夏令時間今天下午2點舉行的 「SCLC中的DL3靶向BiTE療法」 會議上發表兩場口頭演講。關於IMDELLTRA 與 PD-L1 抑制劑聯合治療一線維持廣泛期小細胞肺癌（ES-SCLC）的全球第10期DellPhi-303期研究的新數據將作爲最新摘要（#LBA OA10.04）公佈。此外，對先前接受過治療的ES-SCLC的2期DellPHI-301研究的長期結果將以口頭陳述的形式重點介紹（#OA10 .03）。
譯文內容由第三人軟體翻譯。
